Development and Characterization of Luliconazole Solid Dispersion by DOE Approach for Improved Topical Treatment of Fungal Infections

Abstract

The objective of present research work was to develop solid dispersion of luliconazole (LNZ) by using different concentrations of drug and polymer ratio. The effect of different concentrations of polymers was determined on the drug content and, percentage cumulative drug release. Drug release followed zero-order models and mechanism of drug release are independent on the concentration of a drug. The optimized formulation LNZ-SD-7 is demonstrated particle size50.93 µm, cumulative drug release 99.35±2.54 and drug content of 98.24±2.18 %.Scanning Electron Microscopy reveled optimized LNZ-SD-7was spherical in shape having smooth surfaces. Antifungal studies conformed that LNZ-SDhave better efficacy in treating Candida Albicanshaving MIC-0.4μg ml⁻¹and MBC 0.8μg ml⁻¹compared to A.Niger having MICMIC-1.6 μg ml⁻¹and MBC 3.2 μg ml⁻¹ .Aslo LNZ-SD showed greter zone of inhibition on Candida Albicans when compared to A.niger having zone of inhibition 15 and 9 mm respectively.From the results we may conclude that LNZ-SDcan be used as competent alternative to treat fungal infection caused by Candida albicans as compared and Aspergillus niger. However; further in vivo studies are required to establish its efficacy against fungal infections.